 Connection
Anna Baron to Aged
This is a "connection" page, showing publications Anna Baron has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.056 |
|
|
|
-
Bavry AA, Hess E, W Waldo S, Bar?n AE, Kumbhani DJ, Bhatt DL, Pandey A. Long-term predictive value of stroke volume index obtained from right heart catheterization: Insights from the veterans affairs clinical assessment, reporting, and tracking program. Clin Cardiol. 2020 Oct; 43(10):1126-1132.
Score: 0.050
-
Burke RE, Canamucio A, Glorioso TJ, Bar?n AE, Ryskina KL. Variability in Transitional Care Outcomes Across Hospitals Discharging Veterans to Skilled Nursing Facilities. Med Care. 2020 04; 58(4):301-306.
Score: 0.049
-
Asundi A, Stanislawski M, Mehta P, Mull HJ, Schweizer ML, Bar?n AE, Ho PM, Gupta K, Branch-Elliman W. Development and Validation of a Semi-Automated Surveillance Algorithm for Cardiac Device Infections: Insights from the VA CART program. Sci Rep. 2020 03 24; 10(1):5276.
Score: 0.049
-
Burke RE, Canamucio A, Glorioso TJ, Bar?n AE, Ryskina KL. Transitional Care Outcomes in Veterans Receiving Post-Acute Care in a Skilled Nursing Facility. J Am Geriatr Soc. 2019 09; 67(9):1820-1826.
Score: 0.046
-
Asundi A, Stanislawski M, Mehta P, Bar?n AE, Gold H, Mull H, Ho PM, Gupta K, Branch-Elliman W. Prolonged antimicrobial prophylaxis following cardiac device procedures increases preventable harm: insights from the VA CART program. Infect Control Hosp Epidemiol. 2018 09; 39(9):1030-1036.
Score: 0.044
-
Bar?n AE, Kako S, Feser WJ, Malinowski H, Merrick D, Garg K, Malkoski S, Pretzel S, Siegfried JM, Franklin WA, Miller Y, Wolf HJ, Varella-Garcia M. Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol. 2017 10; 12(10):1512-1523.
Score: 0.041
-
Hegeman TW, Glorioso TJ, Hess E, Bar?n AE, Ho PM, Maddox TM, Bradley SM, Burke RE. Facility-Level Percutaneous Coronary Intervention Readmission Rates Are Not Associated With Facility-Level Mortality: Insights From the VA Clinical Assessment, Reporting, and Tracking (CART) Program. J Am Heart Assoc. 2016 09 14; 5(9).
Score: 0.038
-
Branch-Elliman W, Stanislawski M, Strymish J, Bar?n AE, Gupta K, Varosy PD, Gold HS, Ho PM. Cardiac Electrophysiology Laboratories: A Potential Target for Antimicrobial Stewardship and Quality Improvement? Infect Control Hosp Epidemiol. 2016 09; 37(9):1005-11.
Score: 0.038
-
Barnes GD, Stanislawski MA, Liu W, Bar?n AE, Armstrong EJ, Ho PM, Klein A, Maddox TM, Nallamothu BK, Rumsfeld JS, Tsai TT, Bradley SM. Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circ Cardiovasc Qual Outcomes. 2016 07; 9(4):406-13.
Score: 0.038
-
Bradley SM, Hess E, Winchester DE, Sussman JB, Aggarwal V, Maddox TM, Bar?n AE, Rumsfeld JS, Ho PM. Stress Testing After Percutaneous Coronary Intervention in the Veterans Affairs HealthCare System: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circ Cardiovasc Qual Outcomes. 2015 Sep; 8(5):486-92.
Score: 0.036
-
Risendal BC, Sedjo RL, Giuliano AR, Vadaparampil S, Jacobsen PB, Kilbourn K, Bar?n A, Byers T. Surveillance and beliefs about follow-up care among long-term breast cancer survivors: a comparison of primary care and oncology providers. J Cancer Surviv. 2016 Feb; 10(1):96-102.
Score: 0.035
-
Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Bar?n AE, Chonchol M, Camidge DR. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014 Mar 01; 120(5):664-74.
Score: 0.032
-
Berge EM, Lu X, Maxson D, Bar?n AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M, Camidge DR. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer. 2013 Nov; 14(6):636-43.
Score: 0.031
-
Schenkman M, McFann K, Bar?n AE. PROFILE PD: profile of function and impairment level experience with Parkinson disease--clinimetric properties of a rating scale for physical therapist practice. J Neurol Phys Ther. 2010 Dec; 34(4):182-92.
Score: 0.026
-
Barron MA, Gao D, Springer KL, Patterson JA, Brunvand MW, McSweeney PA, Zeng C, Bar?n AE, Weinberg A. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2009 Dec 15; 49(12):1777-83.
Score: 0.024
-
Byers T, Wolf HJ, Franklin WA, Braudrick S, Merrick DT, Shroyer KR, Hirsch FR, Zeng C, Bar?n AE, Bunn PA, Miller YE, Kennedy TC. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):158-62.
Score: 0.021
-
Bekelman DB, Feser W, Morgan B, Welsh CH, Parsons EC, Paden G, Baron A, Hattler B, McBryde C, Cheng A, Lange AV, Au DH. Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical Trial. JAMA. 2024 01 16; 331(3):212-223.
Score: 0.016
-
Kammer MN, Lakhani DA, Balar AB, Antic SL, Kussrow AK, Webster RL, Mahapatra S, Barad U, Shah C, Atwater T, Diergaarde B, Qian J, Kaizer A, New M, Hirsch E, Feser WJ, Strong J, Rioth M, Miller YE, Balagurunathan Y, Rowe DJ, Helmey S, Chen SC, Bauza J, Deppen SA, Sandler K, Maldonado F, Spira A, Billatos E, Schabath MB, Gillies RJ, Wilson DO, Walker RC, Landman B, Chen H, Grogan EL, Bar?n AE, Bornhop DJ, Massion PP. Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules. Am J Respir Crit Care Med. 2021 12 01; 204(11):1306-1316.
Score: 0.014
-
Hirsch EA, Bar?n AE, Risendal B, Studts JL, New ML, Malkoski SP. Determinants Associated With Longitudinal Adherence to Annual Lung Cancer Screening: A Retrospective Analysis of Claims Data. J Am Coll Radiol. 2021 Aug; 18(8):1084-1094.
Score: 0.013
-
Lahm T, Hess E, Bar?n AE, Maddox TM, Plomondon ME, Choudhary G, Maron BA, Zamanian RT, Leary PJ. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. Chest. 2021 04; 159(4):1586-1597.
Score: 0.013
-
Maron BA, Brittain EL, Hess E, Waldo SW, Bar?n AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Gali? N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020 09; 8(9):873-884.
Score: 0.013
-
Hirsch EA, New ML, Brown SL, Bar?n AE, Sachs PB, Malkoski SP. Impact of a Hybrid Lung Cancer Screening Model on Patient Outcomes and Provider Behavior. Clin Lung Cancer. 2020 11; 21(6):e640-e646.
Score: 0.012
-
Keach JW, Stanislawski MA, Bar?n AE, Plomondon ME, Langner P, Amin A, Gilmartin HM, Waldo S, Maddox TM. Variation in contrast-associated acute kidney injury prophylaxis for percutaneous coronary intervention: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) program. BMC Nephrol. 2020 04 28; 21(1):150.
Score: 0.012
-
Xie JX, Gunzburger EC, Kaun L, Plomondon ME, Bar?n AE, Waldo SW, Virani SS, Maddox TM, Mavromatis K. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
Score: 0.012
-
Hirsch EA, New ML, Brown SP, Bar?n AE, Malkoski SP. Patient Reminders and Longitudinal Adherence to Lung Cancer Screening in an Academic Setting. Ann Am Thorac Soc. 2019 10; 16(10):1329-1332.
Score: 0.012
-
Jones CD, Falvey J, Hess E, Levy CR, Nuccio E, Bar?n AE, Masoudi FA, Stevens-Lapsley J. Predicting Hospital Readmissions from Home Healthcare in Medicare Beneficiaries. J Am Geriatr Soc. 2019 12; 67(12):2505-2510.
Score: 0.012
-
Valle JA, Glorioso TJ, Bricker R, Bar?n AE, Armstrong EJ, Bhatt DL, Rao SV, Plomondon ME, Serruys PW, Keppetein AP, Sabik JF, Dressler O, Stone GW, Waldo SW. Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program. JAMA Cardiol. 2019 08 01; 4(8):727-735.
Score: 0.012
-
Asundi A, Stanislawski M, Mehta P, Baron AE, Mull HJ, Ho PM, Zimetbaum PJ, Gupta K, Branch-Elliman W. Real-world effectiveness of infection prevention interventions for reducing procedure-related cardiac device infections: Insights from the veterans affairs clinical assessment reporting and tracking program. Infect Control Hosp Epidemiol. 2019 08; 40(8):855-862.
Score: 0.012
-
Hu PT, Jones WS, Glorioso TJ, Bar?n AE, Grunwald GK, Waldo SW, Maddox TM, Vidovich M, Banerjee S, Rao SV. Predictors and Outcomes of Staged?Versus One-Time Multivessel?Revascularization in Multivessel?Coronary?Artery Disease: Insights From the VA CART Program. JACC Cardiovasc Interv. 2018 11 26; 11(22):2265-2273.
Score: 0.011
-
Scott KA, Fisher GG, Bar?n AE, Tompa E, Stallones L, DiGuiseppi C. The Associations Between Falls, Fall Injuries, and Labor Market Outcomes Among U.S. Workers 65 Years and Older. J Occup Environ Med. 2018 10; 60(10):943-953.
Score: 0.011
-
Prouse AF, Langner P, Plomondon ME, Ho PM, Valle JA, Bar?n AE, Armstrong EJ, Waldo SW. Temporal trends in the management and clinical outcomes of lower extremity arterial thromboembolism within a national Veteran population. Vasc Med. 2019 02; 24(1):41-49.
Score: 0.011
-
Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018 09 01; 78(17):4971-4983.
Score: 0.011
-
Leary PJ, Hess E, Bar?n AE, Branch KR, Choudhary G, Hough CL, Maron BA, Ralph DD, Ryan JJ, Tedford RJ, Weiss NS, Zamanian RT, Lahm T. H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. Am J Respir Crit Care Med. 2018 06 15; 197(12):1638-1641.
Score: 0.011
-
Gunja A, Stanislawski MA, Bar?n AE, Maddox TM, Bradley SM, Vidovich MI. The implications of cocaine use and associated behaviors on adverse cardiovascular outcomes among veterans: Insights from the VA Clinical Assessment, Reporting, and Tracking (CART) Program. Clin Cardiol. 2018 Jun; 41(6):809-816.
Score: 0.011
-
Smith DE, Golden AP, Stange AW, Barker E, Mroz M, Bar?n AE, Ghosh D, Maier L, Cragle D, Newman LS. Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT). Am J Ind Med. 2018 07; 61(7):592-604.
Score: 0.011
-
Raghavan S, Liu WG, Michael Ho P, Plomondon ME, Bar?n AE, Caplan L, Joynt Maddox KE, Magid D, Saxon DR, Voils CI, Bradley SM, Maddox TM. Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. J Diabetes Complications. 2018 05; 32(5):480-487.
Score: 0.011
-
Scott KA, Fisher GG, Bar?n AE, Tompa E, Stallones L, DiGuiseppi C. Same-level fall injuries in US workplaces by age group, gender, and industry. Am J Ind Med. 2018 02; 61(2):111-119.
Score: 0.010
-
Ventetuolo CE, Hess E, Austin ED, Bar?n AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, Zamanian RT, Choudhary G, Maron BA. Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. PLoS One. 2017; 12(11):e0187734.
Score: 0.010
-
Opotowsky AR, Hess E, Maron BA, Brittain EL, Bar?n AE, Maddox TM, Alshawabkeh LI, Wertheim BM, Xu M, Assad TR, Rich JD, Choudhary G, Tedford RJ. Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice: An Analysis of Mortality From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol. 2017 10 01; 2(10):1090-1099.
Score: 0.010
-
Armstrong EJ, Stanislawski MA, Kokkinidis DG, Plomondon ME, Bar?n AE, Giri J, Shunk KA, Banerjee S, Maddox TM, Waldo SW. Coronary atherectomy is associated with improved procedural and clinical outcomes among patients with calcified coronary lesions: Insights from the VA CART program. Catheter Cardiovasc Interv. 2018 05 01; 91(6):1009-1017.
Score: 0.010
-
Xie JX, Glorioso TJ, Dattilo PB, Aggarwal V, Ho PM, Bar?n AE, Donaldson D, Armstrong EJ, Klein A, Giri J, Tsai TT. Effect of Chronic Kidney Disease on Mortality in Patients Who Underwent Lower Extremity Peripheral Vascular Intervention. Am J Cardiol. 2017 02 15; 119(4):669-674.
Score: 0.010
-
Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Bar?n AE, Rumsfeld JS, Choudhary G. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016 Mar 29; 133(13):1240-8.
Score: 0.009
-
McCoach CE, Berge EM, Lu X, Bar?n AE, Camidge DR. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry. J Thorac Oncol. 2016 Mar; 11(3):407-13.
Score: 0.009
-
Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan; 9(1):96-104.
Score: 0.009
-
Rikke BA, Wynes MW, Rozeboom LM, Bar?n AE, Hirsch FR. Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. Biomark Med. 2015; 9(8):751-61.
Score: 0.009
-
Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Bar?n AE, Yeh N, Gaspar LE, Liu AK, Ney DE, Damek DM, Lillehei KO, Kavanagh BD. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):894-902.
Score: 0.008
-
Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Bar?n AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014 Jun; 167(6):810-7.
Score: 0.008
-
Vigen R, O'Donnell CI, Bar?n AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013 Nov 06; 310(17):1829-36.
Score: 0.008
-
Clarke CL, Grunwald GK, Allen LA, Bar?n AE, Peterson PN, Brand DW, Magid DJ, Masoudi FA. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013 Nov; 6(6):680-6.
Score: 0.008
-
Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy TC, Feser WJ, Baron AE, Franklin WA, Brock MV, Herman JG, Baylin SB, Byers T, Stidley CA, Belinsky SA. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res. 2012 Jun 15; 18(12):3387-95.
Score: 0.007
-
Schenkman M, Ellis T, Christiansen C, Bar?n AE, Tickle-Degnen L, Hall DA, Wagenaar R. Profile of functional limitations and task performance among people with early- and middle-stage Parkinson disease. Phys Ther. 2011 Sep; 91(9):1339-54.
Score: 0.007
-
Boyko EJ, Alderman BW, Keane EM, Baron AE. Effects of childbearing on glucose tolerance and NIDDM prevalence. Diabetes Care. 1990 Aug; 13(8):848-54.
Score: 0.006
-
Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Bar?n AE, Belinsky SA, Miller YE, Byers T, Franklin WA. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. Cancer Prev Res (Phila). 2010 Apr; 3(4):447-53.
Score: 0.006
-
Massion PP, Zou Y, Uner H, Kiatsimkul P, Wolf HJ, Baron AE, Byers T, Jonsson S, Lam S, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M. Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. PLoS One. 2009 Jun 09; 4(6):e5611.
Score: 0.006
-
Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther. 2008 Dec; 7(12):3685-94.
Score: 0.006
-
Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Bar?n AE, Drabkin HA. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008 Nov; 22(11):2041-7.
Score: 0.005
-
Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Bar?n AE, Lucia MS, Thompson IM, Leach RJ. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res. 2008 May 15; 14(10):3223-9.
Score: 0.005
-
Chen C, Kane M, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG, Raben D. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol. 2007 Nov 01; 25(31):4880-6.
Score: 0.005
-
Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007 Aug 06; 97(3):391-7.
Score: 0.005
-
Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
Score: 0.005
-
Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Bar?n AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006 May 15; 12(10):3078-84.
Score: 0.005
-
Gruber MP, Coldren CD, Woolum MD, Cosgrove GP, Zeng C, Bar?n AE, Moore MD, Cool CD, Worthen GS, Brown KK, Geraci MW. Human lung project: evaluating variance of gene expression in the human lung. Am J Respir Cell Mol Biol. 2006 Jul; 35(1):65-71.
Score: 0.005
-
Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005 Aug 01; 62(5):1371-8.
Score: 0.004
-
Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Bar?n AE, Jones RB. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biol Blood Marrow Transplant. 2005 Apr; 11(4):297-306.
Score: 0.004
-
Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8.
Score: 0.004
-
Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37.
Score: 0.004
-
Gottlieb SL, Douglas JM, Foster M, Schmid DS, Newman DR, Baron AE, Bolan G, Iatesta M, Malotte CK, Zenilman J, Fishbein M, Peterman TA, Kamb ML. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004 Sep 15; 190(6):1059-67.
Score: 0.004
-
Johnson DW, Cagnoni PJ, Schossau TM, Stemmer SM, Grayeb DE, Baron AE, Shpall EJ, Bearman SI, McDermitt J, Jones RB. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant. 1999 Oct; 24(7):785-92.
Score: 0.003
-
Marine WM, Kerwin EM, Moore EE, Lezotte DC, Baron AE, Grosso MA. Mandatory seatbelts: epidemiologic, financial, and medical rationale from the Colorado matched pairs study. J Trauma. 1994 Jan; 36(1):96-100.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|